# GSK completes acquisition of Affinivax

- Link: https://www.directorstalkinterviews.com/gsk-completes-acquisition-of-affinivax/4121077744
- Published: 2022-08-16T07:22:29+01:00
- Author: Amilia Stone

**[GSK plc](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)**(
[LON:GSK](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l))
has announced it has completed the acquisition of Affinivax, Inc, a clinical-stage
biopharmaceutical company based in Cambridge (Boston, Massachusetts). Affinivax 
has pioneered the development of a novel class of vaccines, the most advanced of
which are next-generation pneumococcal vaccines.

As previously announced, the acquisition of Affinivax aligns with GSK’s strategy
of building a strong portfolio of specialty medicines and vaccines. It includes 
a next-generation 24-valent pneumococcal vaccine candidate (AFX3772), currently 
in phase II development, which is based on the highly innovative Multiple Antigen
Presenting System (MAPS^(TM)) platform technology. A 30-plus valent pneumococcal
candidate vaccine is also in pre-clinical development.

The MAPS^(TM) technology supports higher valency than conventional conjugation technologies,
potentially enabling broader coverage against prevalent pneumococcal serotypes and
generating higher antibody responses against many individual serotypes than current
pneumococcal vaccines.

In the adult phase I/II clinical trials, AFX3772 was well tolerated in participants
and demonstrated good immune responses compared to the current standard of care.
In July 2021, the US Food and Drug Administration granted Breakthrough Therapy designation
for AFX3772 to prevent S. pneumoniae invasive disease and pneumonia in adults 50
years and above. Preparations for the start of the phase III program are underway.
Phase II clinical trials started in June 2022 to assess the use of the vaccine in
the paediatric population.

**Financial considerations**

Under the terms of the agreement, GSK has acquired 100% of the outstanding shares
of Affinivax. The acquisition comprised an upfront payment of $2.1 billion paid 
upon closing and two potential milestone payments of $0.6 billion to be paid upon
the achievement of certain paediatric clinical development milestones. The transaction
was subject to customary closing conditions, including the expiration or early termination
of the waiting period under the Hart-Scott- Rodino Anti-Trust Improvements Act of
1976. GSK will account for the transaction as a business combination.

**Pneumococcal disease**

Pneumococcal disease is an umbrella term used to describe any infection caused by
the bacteria _Streptococcus pneumoniae_, a leading cause of acute bacterial infections
worldwide. It has a broad clinical spectrum including bloodstream infections (sepsis),
pneumonia, meningitis, and other milder diseases such as sinusitis and otitis media.
A broadly recognized unmet medical need remains despite the availability of current
vaccines. Pneumococcal pneumonia causes an estimated 150,000 hospitalisations each
year in the United States; pneumococcal meningitis and bacteremia killed approximately
3,250 people in the United States in 2019^([1]).

**MAPS****^(TM)** **technology platform**

Multiple Antigen Presenting System (MAPS) is a novel and highly efficient vaccine
technology platform that enables the precise, high-affinity binding of pathogen-
derived polysaccharides and proteins of immune-relevance into a single vaccine. 
Immunisation with the resulting polysaccharide-protein complexes induces a broad
and potentially protective B-cell (antibody) response to the polysaccharides and
a separate B-cell and T-cell immune response to the proteins. The distinctive plug-
and-play nature of MAPS^(TM) enables the targeting of a broad range of infectious
diseases.

The initial use of the technology has been directed primarily toward preventing 
pneumococcal disease. Applicability of the technology has also been demonstrated
for additional infectious disease pathogens, including those that cause hospital-
acquired infections.

> **Tony Wood, Chief Scientific Officer, GSK**, said: “Affinivax’s exciting pneumococcal
> vaccine candidates, the potentially disruptive MAPs technology and their fantastic
> scientific talent, further strengthen our pipeline of novel vaccines and presence
> in the Boston area”.

Share on:
